ReShape Lifesciences Inc. Announces $200,000 Loan Agreement with Vyome Therapeutics to Support Upcoming Merger

Reuters07-04

<a href="https://laohu8.com/S/RSLS">ReShape Lifesciences</a> Inc. Announces $200,000 Loan Agreement with Vyome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Support Upcoming Merger

ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-K filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065782), on July 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2548387381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-04 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548387381","market":"fut","top_or_hot":-1,"title":"ReShape Lifesciences Inc. Announces $200,000 Loan Agreement with Vyome Therapeutics to Support Upcoming Merger","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RSLS\">ReShape Lifesciences</a> Inc. Announces $200,000 Loan Agreement with Vyome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Support Upcoming Merger\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065782), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ReShape Lifesciences Inc. Announces $200,000 Loan Agreement with Vyome Therapeutics to Support Upcoming Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReShape Lifesciences Inc. Announces $200,000 Loan Agreement with Vyome Therapeutics to Support Upcoming Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-04 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RSLS\">ReShape Lifesciences</a> Inc. Announces $200,000 Loan Agreement with Vyome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Support Upcoming Merger\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065782), on July 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nNDL5tc2FM:1","article_id":"2548387381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548387381","pubTimestamp":1751573206,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-K filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备"},"translate_title":"ReShape Lifesciences Inc.宣布与Vyome Therapeutics达成20万美元贷款协议，以支持即将到来的合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSLS":0.9},"content_text":"ReShape Lifesciences Inc. Announces $200,000 Loan Agreement with Vyome Therapeutics to Support Upcoming Merger\n    \n\n        ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-K filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065782), on July 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548387381","isCrawlerRequest":true}